13.10.2022 • NewsCelaneseDuPontspecialty materials

EU Clears Celanese’s Purchase of DuPont’s Mobility and Materials Business

The European Commission has cleared Celanese’s proposed purchase of DuPont’s Mobility and Materials (M&M) business after the former agreed to sell its global thermoplastic copolymer business to allay competition fears.

Celanese is planning to divest the business, which includes a production facility in Ferrara, Italy, and the Pibiflex and Riteflex brands, to Italian engineering plastics producer Taro Plast. The Commission will have to formally approve Taro Plast as the buyer in a separate process.

Executive vice-president Margrethe Vestager, in charge of competition policy for the EU, said: “Celanese and DuPont's Mobility and Materials business compete head to head in the supply of thermoplastic copolyester, an essential input for the automobile sector. With their transaction, they would have a combined leading position in the market with only a few alternative suppliers. The commitments offered by Celanese, divesting a stand-alone business, fully remove our competition concerns as they ensure that a player will remain in the market.”

The Commission’s investigation showed that the companies compete in supplying the thermoplastics to the automotive, industrial and commercial, electric and electronic, and consumer markets.

DuPont agreed in February to sell most of its M&M business to Celanese for $11 billion. The sale was originally expected to close by the end of this year.

Author: Elaine Burridge, Freelance Journalist

© DuPont
© DuPont

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.